Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

DOSTARLIMAB-GXLY vs DOXEPIN: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

DOSTARLIMAB-GXLY vs DOXEPIN: Safety Overview

Metric DOSTARLIMAB-GXLY DOXEPIN
Total FAERS Reports 504 4,021
Deaths Reported 55 1,613
Death Rate 10.9% 40.1%
Hospitalizations 126 1,091
Average Patient Age 67.4 yrs 49.2 yrs
% Female Patients 92.7% 63.8%
FDA Approval Date N/A Approved Prior to Jan 1, 1982
Manufacturer N/A Teva Pharmaceuticals USA, Inc.
Route N/A TOPICAL
Marketing Status Prescription Discontinued